Elevation Oncology Inc ELEV
Dividend Summary
There have not been any declared dividends recently.
Summary | Previous dividend | Next dividend |
---|---|---|
Status | – | – |
Type | – | – |
Per share | – | – |
Declaration date | – | – |
Ex-div date | – | – |
Pay date | – | – |
Enter the number of Elevation Oncology Inc shares you hold and we'll calculate your dividend payments:
Sign up for Elevation Oncology Inc and we'll email you the dividend information when they declare.
Add Elevation Oncology Inc to receive free notifications when they declare their dividends.
Your account is set up to receive Elevation Oncology Inc notifications.
Status | Type | Decl. date | Ex-div date | Pay date | Decl. Currency | Forecast amount | Decl. amount | Accuracy |
---|---|---|---|---|---|---|---|---|
There are no Elevation Oncology Inc dividends. |
Year | Amount | Change |
---|---|---|
2006 | 0.0c | — |
2007 | 0.0c | 0% |
2008 | 0.0c | 0% |
2009 | 0.0c | 0% |
2010 | 0.0c | 0% |
2011 | 0.0c | 0% |
2012 | 0.0c | 0% |
2013 | 0.0c | 0% |
2014 | 0.0c | 0% |
2015 | 0.0c | 0% |
2016 | 0.0c | 0% |
2017 | 0.0c | 0% |
2018 | 0.0c | 0% |
2019 | 0.0c | 0% |
2020 | 0.0c | 0% |
2021 | 0.0c | 0% |
2022 | 0.0c | 0% |
2023 | 0.0c | 0% |
2024 | Sign Up Required |
Elevation Oncology Inc Optimized Dividend Chart
- Dividend Yield Today
- 0.0%
- Optimized Yield
- Sign Up Required
- 52 Week High
- 0.0% on 14 October 2023
- 52 Week Low
- 0.0% on 14 October 2023
- Next Ex-Div-Date Countdown
- Sign Up Required
About Elevation Oncology Inc
Elevation Oncology, Inc is a clinical stage biopharmaceutical company. The Company is focused on the development of targeted therapeutics for the treatment of cancer in genomically-defined patient populations. It is focuses on identifying oncogenic drivers with other driver alterations and in the conduct of clinical trials. The Company’s lead program is focused on neuregulin-1 (NRG1), fusions, which are genomic alterations that are identified as oncogenic driver alterations. Its NRG1 is the primary activating ligand of HER3. The Company's clinical trial, CRESTONE, is a Phase II study of seribantumab in cancer patients with a solid tumor of any origin that expresses a genomic change called an NRG1 fusion.
- Sector
- Pharmaceuticals & Biotechnology
- Country
- United States
- Share Price
- $0.51 (yesterday's closing price)
- Shares in Issue
- 59 million
- Market Cap
- $30mn
- 0
- Market Indices
- none